Dclre1c Inhibitors
DCLRE1C Inhibitors constitute a class of compounds designed to modulate the activity of the DCLRE1C gene, crucial for V(D)J recombination and DNA repair. These inhibitors aim to interfere with specific biochemical and cellular pathways associated with DCLRE1C. At the core of this inhibitor class are compounds such as Camptothecin, Etoposide, Bleomycin, and Mitoxantrone, targeting topoisomerases involved in DNA replication and repair. By inhibiting these enzymes, these compounds directly or indirectly impede DCLRE1C function, potentially disrupting the intricate processes of V(D)J recombination and DNA repair. Inhibitors like 3-[3-[4-[(Methylamino)methyl]phenyl]-5-isoxazolyl]-5-[4-[(1-methylethyl)sulfonyl]phenyl]-2-pyrazinamine, DNA-PK Inhibitor (NU7441), Olaparib, and ATRX Inhibitor (VE-822) focus on key kinases involved in DNA damage responses. Their action on ATR, DNA-PK, and PARP interferes with the activation of DNA repair pathways, indirectly influencing DCLRE1C function.
Mirin and KU-60019, targeting MRE11 and ATM kinase, respectively, contribute to the class by disrupting specific components of the DNA repair machinery. Their influence on the MRN complex and ATM-mediated pathways may impact DCLRE1C-mediated processes, shedding light on potential mechanisms for gene regulation. Additionally, compounds like Doxorubicin and Zeocin induce DNA damage, triggering DNA damage responses that indirectly affect DCLRE1C function. These chemicals exemplify the interconnectedness between DNA damage induction and the intricate processes governed by DCLRE1C. In summary, DCLRE1C Inhibitors encompass a diverse array of compounds targeting key components of DNA repair and recombination pathways. Understanding their intricate interactions with DCLRE1C provides valuable insights into potential discovery, opening new possibilities for addressing disorders associated with DCLRE1C dysfunction.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin inhibits DNA topoisomerase I, disrupting DNA replication and repair processes. Its direct impact on DCLRE1C involves hindering the resolution of DNA structures, potentially inhibiting the protein's role in V(D)J recombination and DNA repair. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide inhibits topoisomerase II, disrupting DNA repair mechanisms. Its indirect influence on DCLRE1C involves impeding DNA damage response pathways, potentially affecting the protein's role in V(D)J recombination and DNA repair. | ||||||
Bleomycin | 11056-06-7 | sc-507293 | 5 mg | $275.00 | 5 | |
Bleomycin induces DNA strand breaks and inhibits DNA synthesis. Its indirect impact on DCLRE1C involves triggering DNA damage responses, potentially interfering with the protein's role in V(D)J recombination and DNA repair. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $285.00 | 8 | |
Mitoxantrone inhibits topoisomerase II, inducing DNA damage. Its indirect influence on DCLRE1C involves disrupting DNA repair pathways, potentially impacting the protein's role in V(D)J recombination and DNA repair. | ||||||
Ceralasertib | 1352226-88-0 | sc-507439 | 10 mg | $573.00 | ||
AZD6738 inhibits ATR kinase, impairing DNA damage responses. Its indirect impact on DCLRE1C involves hindering the activation of DNA repair pathways, potentially affecting the protein's role in V(D)J recombination and DNA repair. | ||||||
NU 7441 | 503468-95-9 | sc-208107 | 5 mg | $357.00 | 10 | |
NU7441 inhibits DNA-PK, affecting non-homologous end joining (NHEJ). Its direct influence on DCLRE1C involves suppressing NHEJ, potentially inhibiting the protein's role in V(D)J recombination and DNA repair. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib inhibits PARP, impairing DNA repair processes. Its indirect impact on DCLRE1C involves disrupting the base excision repair pathway, potentially affecting the protein's role in V(D)J recombination and DNA repair. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin inhibits topoisomerases and induces DNA damage. Its indirect influence on DCLRE1C involves triggering DNA damage responses, potentially interfering with the protein's role in V(D)J recombination and DNA repair. | ||||||
KU 60019 | 925701-46-8 | sc-363284 sc-363284A | 10 mg 50 mg | $248.00 $1035.00 | 1 | |
KU-60019 inhibits ATM kinase, impairing DNA damage responses. Its indirect impact on DCLRE1C involves hindering the activation of DNA repair pathways, potentially affecting the protein's role in V(D)J recombination and DNA repair. | ||||||